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Dysfunctional mTORC1 signaling is associated with
a number of human pathologies owing to its central
role in controlling cell growth, proliferation, and
metabolism. Regulation of mTORC1 is achieved by
the integration of multiple inputs, including those of
mitogens, nutrients, and energy. It is thought that
agents that increase the cellular AMP/ATP ratio,
such as the antidiabetic biguanides metformin and
phenformin, inhibit mTORC1 through AMPK activa-
tion of TSC1/2-dependent or -independent mecha-
nisms. Unexpectedly, we found that biguanides
inhibit mTORC1 signaling, not only in the absence
of TSC1/2 but also in the absence of AMPK. Consis-
tent with these observations, in two distinct preclin-
ical models of cancer and diabetes, metformin acts
to suppressmTORC1 signaling in an AMPK-indepen-
dent manner. We found that the ability of biguanides
to inhibit mTORC1 activation and signaling is,
instead, dependent on the Rag GTPases.INTRODUCTION
Increased mammalian target of rapamycin (mTOR) signaling has
been implicated in a number of specific human pathologies,
including obesity, type 2 diabetes, and cancer (Dann et al.,
2007; Marshall, 2006; Um et al., 2006; Wullschleger et al.,
2006). mTOR exists in two complexes that consist of distinct
sets of protein binding partners (Dann et al., 2007; Sabatini,
2006). The first, mTORC1, is rapamycin sensitive and is thought
to mediate many of its downstream effects through S6 kinase 1
(S6K1) and initiation factor 4E-binding protein 1 (4E-BP1)390 Cell Metabolism 11, 390–401, May 5, 2010 ª2010 Elsevier Inc.(Um et al., 2006; Wullschleger et al., 2006). In contrast, mTORC2
is largely rapamycin resistant and mediates phosphorylation of
protein kinase B (PKB/Akt) S473, one of two phosphorylated
residues required for full PKB/Akt activation (Sarbassov et al.,
2005). Although both complexes respond to hormones and
growth factors, only mTORC1 responds positively to nutrients
and cellular energy status (Um et al., 2006), metabolic parame-
ters intimately linked to obesity, diabetes, and cancer (Dann
et al., 2007; Um et al., 2006).
Many mitogens initiate mTORC1 signaling by the sequential
activation of class 1 phosphatidylinositol kinase (PI3K) and
PKB/Akt, which reverses the inhibitory effects of tuberous scle-
rosis complex proteins 1 and 2 (TSC1/2) (Manning and Cantley,
2007) and proline-rich PKB/Akt substrate 40 kDa (PRAS40) on
mTORC1 (Vander Haar et al., 2007; Sancak et al., 2007). This
allows activation of Ras homolog enriched in brain (Rheb),
required for mTORC1 activation (Garami et al., 2003; Long
et al., 2005), whereas PRAS40 suppression relieves its inhibitory
effects on mTORC1 (Haas and Hagedorn, 1992; Sancak et al.,
2007). Nutrients, unlike insulin, have been shown to mediate
mTORC1 signaling through class 3 PI3K, hVps34 (Byfield et al.,
2005; Nobukuni et al., 2005), and, more recently, Rag GTPases
(Kim et al., 2008; Sancak et al., 2008). Apart from insulin and
nutrients, cellular energy status is a key regulator of mTORC1
signaling (Dennis et al., 2001). Initially, we demonstrated that
mTORC1 signaling is blunted in response to the inhibition of
glycolytic flux and ATP production (Dennis et al., 2001). More-
over, employing S6K1 or 4E-BP1 as in vitro substrates revealed
that mTOR possessed a high Km for ATP in the presence of Mg
2+
(Dennis et al., 2001). We hypothesized that direct sensing of ATP
by mTOR could be one mechanism whereby intracellular ATP
levels were maintained in a homeostatic narrow range. However,
inhibition of glycolytic flux also leads to increased intracellular
AMP levels and activation of AMP-activated kinase (AMPK)
(Hardie, 2008; Steinberg and Kemp, 2009). In turn AMPK
Figure 1. Oligomycin-Induced dS6K Dephosphorylation Does Not
Require dTSC1/2
(A) Alignment of Drosophila TSC2 (accession number NP_524177) with the
mouse TSC2, isoform 1 (accession number NP_035777). Percentage of
sequence identity and similarity (parentheses) of different regions of TSC2
are indicated. The major AMPK phosphorylation sites in TSC2 reported to
be affected by energy depletion are in bold and underlined. The mouse 1271
and 1366 phosphorylation sites correspond to the respective rat 1227 and
1345 sites described by Inoki et al. (2003). GAP denotes the GTPase-activating
domain.
(B) Analysis of dS6K activity following treatment of Kc167 cells with 10 mM
oligomycin for 30 min or 100 nM insulin for 30 min. In samples containing
100 nM insulin plus 10 mM oligomycin, the inhibitor was added for the indicated
time prior to the 30 min insulin treatment. Rapamycin (20 nM) was added
15 min prior to 30 min insulin treatment. Western blot analysis of dS6K T398
phosphorylation and dS6K are as indicated.
(C) Analysis of dS6K activity following dTsc1, dTsc2 dsRNA treatment in
the absence or presence of either 100 nM insulin or 10 mM oligomycin for
30 min. Western blot analysis of dS6K T398 phosphorylation, dS6K activity,
dS6K, and dTSC1 are as indicated. The data shown are representative of
two independent experiments.
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Metformin Inhibits mTORC1 Independent of AMPKphosphorylates TSC2, attenuating downstream signaling, by an
as-yet-unknown mechanism (Inoki et al., 2003).
Elucidating the role of mTORC1 in response to energy
depletion is critical because of the broad clinical use of the anti-
diabetic drug metformin (Libby et al., 2009; Shackelford and
Shaw, 2009). Metformin and its more hydrophobic analog, phen-
formin, are biguanides. They inhibit mitochondrial respiratory
chain complex I, which reduces ATP production, thus resulting
in the activation of AMPK (Hardie, 2008). The major action of
metformin in the treatment of type 2 diabetes is to decrease
hepatic glucose output and to increase intestinal glycolytic
lactate production as well as peripheral tissue insulin-dependent
glucose uptake (Bailey and Turner, 1996). Moreover, AMPK acti-
vation by metformin leads to the inhibition of mTORC1 (Tzatsos
and Kandror, 2006) in a TSC1/2-dependent manner (Dowling
et al., 2007), seemingly consistent with the earlier findings
described above for other energy-depleting agents (Inoki et al.,
2003). The observation that metformin inhibits mTORC1 sig-
naling has drawn attention to its potential use as an anticancer
agent (Dann et al., 2007; Shackelford and Shaw, 2009). Clinically,
this concept is supported by retrospective record-linkage case-
control studies demonstrating that metformin treatment of dia-
betic patients reduced the risk of certain cancers (Bowker
et al., 2006; Libby et al., 2009), whereas insulin mimetics could
increase such risks.
Although a role for TSC1/2 in mediating the inhibitory input to
mTORC1 in response to energy depletion in mammalian cells is
well documented (Inoki et al., 2003; Dowling et al., 2007), the
AMPK phosphorylation sites are not conserved in Drosophila
TSC2, dTsc2 (Um et al., 2006). Moreover, in direct contradiction
to the findings of Dowling et al. (Dowling et al., 2007), others have
shown that the biguanides inhibit this response via a TSC2-inde-
pendent pathway, through AMPK phosphorylation of raptor, an
mTORC1 constituent (Gwinn et al., 2008). Based on these obser-
vations, we set out to examine the role of TSC1/2 and AMPK in
mediating the inhibition of mTORC1 signaling by AMPK activa-
tors, particularly phenformin and metformin. We found that
mTORC1 inhibition by biguanides is independent of TSC1/2
and, unexpectedly, independent of AMPK. Instead, we found
that biguanides abolish mTORC1 activation in a Rag GTPase-
dependent manner.
RESULTS
dTSC1/dTSC2 Are Not Essential for dTORC1 Inhibition
by Energy Depletion
mTORC1 signaling is highly conserved from Drosophila to man
(Montagne and Thomas, 2004; Pan and Hardie, 2002). However,
Drosophila dTsc2 lacks the AMPK phosphorylation sites equiva-
lent to mammalian TSC2 T1227 and S1345, as well as the
encompassing sequence (Figure 1A). Therefore, we investigated
the ability of oligomycin, an inhibitor of mitochondrial oxidative
phosphorylation, to inhibit dTORC1 signaling in Drosophila
Kc167 cells, as compared to rapamycin. Basal and insulin-
induced activation of dTORC1 signaling, as measured by
dS6K T398 phosphorylation or dS6K activity, were inhibited to
the same extent by oligomycin as they were by rapamycin
(Figure 1B), although in the former case dTORC1 activity began
to recover with time (see below). The glycolytic inhibitor 2-deoxy-Cglucose (2DG), like oligomycin, also inhibited dS6K T398
phosphorylation (data not shown). To determine whether the
effects of oligomycin were mediated through dTsc1/dTsc2, we
treated Kc167 cells with double-stranded RNA (dsRNA) to
deplete their protein levels. As previously reported (Gao et al.,
2002; Radimerski et al., 2002), depletion of either protein
enhanced dS6K activity but did not alter inhibition by oligomycin
(Figure 1C). Depletion of dTsc1 was detected with antibodies,
and though there are no appropriate antibodies to detect endog-
enous dTsc2 (Figure 1C), consistent with others (Gao et al., 2002),
dTsc1 protein levels decreased in cells treated with dsRNA
against dTsc2 (Figure 1C). These findings indicated that energyell Metabolism 11, 390–401, May 5, 2010 ª2010 Elsevier Inc. 391
Figure 2. TSC2 Is Not Required for Downregulation of S6K1 T389 by Energy-Depleting Agents
(A and B) (A) TSC2+/+ or TSC2/ MEFs were treated with either 10 mM oligomycin or (B) 100 mM 2DG for the times indicated.
(C) TSC2+/+ or TSC2/ MEFs were treated with the indicated concentrations of 2DG for 30 min.
(D) Western blot analysis of the indicated proteins in TSC2+/+ and TSC2/ MEFs.
(E and F) TSC2+/+ MEFs were treated with either 10 mM oligomycin or 25 mM 2DG at the indicated times. Asterisk denotes the addition of a fresh aliquot of either
ATP-depleting agent following a 60 min incubation with the initial inhibitor. The data shown are representative of at least three independent experiments.
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manner.
TSC2 Is Not Required for mTORC1 Inhibition
by Energy-Depleting Agents
As previously reported (Gao et al., 2002; Jaeschke et al., 2002),
TSC2/ mouse embryonic fibroblasts (MEFs) exhibited ele-
vated levels of S6K1 T389 phosphorylation as compared to
TSC2+/+ MEFs (Figure 2A). However, the addition of oligomycin
was as efficient in inducing S6K1 T389 dephosphorylation, and
AMPK T172 phosphorylation, in TSC2/ MEFs as in TSC2+/+
MEFs (Figure 2A). Moreover, as in Drosophila cells (Figure 1B),392 Cell Metabolism 11, 390–401, May 5, 2010 ª2010 Elsevier Inc.the effect of oligomycin appeared to be transient (Figure 2A).
Although mitochondrial oxidative phosphorylation produces
ATP more efficiently than glycolysis, most cultured cells depend
on both processes (Schieke et al., 2006). Consistent with this,
100 mM 2DG inhibited mTORC1 to a similar extent as oligomy-
cin, with its activity recovering over time (Figure 2B). Others
have shown that TSC2/ MEFs are resistant to lower concen-
trations of 2DG and have attributed the sensitivity of higher
concentrations to osmotic shock (Inoki et al., 2003). Although
we also found that mTORC1 is more resistant to lower concen-
trations of 2DG in TSC2/ versus TSC2+/+ MEFs (Figure 2C),
this was not the case for low concentrations of oligomycin
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Metformin Inhibits mTORC1 Independent of AMPK(Figure 2A). Because oligomycin and 2DG use distinct mecha-
nisms to inhibit ATP production, this raised the possibility that
in TSC2/ MEFs there was an inherent genetic alteration that
confers 2DG resistance. It has been reported that mTORC1
activation in TSC2/ MEFs leads to the increased expression
of HIF-1a and its glycolytic targets, including hexokinase-II
(HKII) (Brugarolas and Kaelin, 2004). Importantly, HKII binds
glucose, which is competitively inhibited by 2DG (Manuel y
Keenoy et al., 1992). Thus, increases in HKII levels could be
responsible for conferring resistance to inhibition of glycolysis
by 2DG (Maher et al., 2007). We find that as TSC2/ MEFs,
versus TSC2+/+, became confluent HKII levels increased about
2-fold, as compared to either S6K1 or tubulin, which may
explain their resistance to 2DG (Figure 2D and see Figure S1
available online). In parallel, we asked whether mitochondrial
oxidative phosphorylation and glycolysis act together to main-
tain mTORC1 signaling. We found that treatment with oligomy-
cin or 2DG, followed by addition of the other inhibitor 60 min
later, blunted the recovery in mTORC1 signaling, whereas a
second addition of the same inhibitor had little effect (Fig-
ures 2E and 2F, respectively). Together, the results show that
both glycolysis and mitochondrial oxidative phosphorylation
are utilized to maintain mTORC1 activation, and that the
acute inhibition of mTORC1 signaling by blocking either ATP-
producing process is largely independent of TSC1/TSC2.
Effect of Metformin and Phenformin on mTORC1
Signaling in TSC2/ MEFs
As oligomycin inhibits mTORC1 signaling in TSC2/ MEFs,
such cells would be expected to be sensitive to metformin, as
reported for its hydrophobic derivative phenformin (Gwinn
et al., 2008). However, Dowling and colleagues showed that
TSC2/ MEFs were resistant to metformin inhibition of mTORC1
signaling (Dowling et al., 2007). In contrast, we found that treating
TSC2+/+ or TSC2/ MEFs with metformin for 24 hr, or phenfor-
min for 1 hr, led to the inhibition of mTORC1 in both cell types
(Figures 3A and 3B). In parallel, AMPK T172 phosphorylation
and phosphorylation of its substrate acetyl coenzyme A carbox-
ylase (ACC) at S79 increased (Figures 3A and 3B). To understand
the basis for the discrepancy between our findings and those of
Dowling et al. (Dowling et al., 2007), we explored a number of
parameters including metformin dosage, culture conditions,
and cell density. We found that as TSC2/ MEFs become
confluent, mTORC1 signaling becomes sensitive to metformin,
whereas metformin’s ability to induce ACC S79 phosphorylation
was enhanced (Figure 3C). Neither mTORC1 inhibition nor AMPK
activation was influenced by media constituents, as replenish-
ment of fresh media at the time of metformin addition did not alter
either response in confluent cells (Figure 3D). It is known that
oxygen consumption increases with cell density, leading to
a hypoxic milieu and induction of HIF-1a (Dayan et al., 2009).
Moreover, the induction of HIF-1a by hypoxia is amplified in
TSC2/ MEFs (Brugarolas et al., 2003), consistent with the
increase in HKII, a HIF-1a target, that we saw as these cells
become more confluent (Figure S1). Such a rise in HKII would
be expected to increase a tumor cell’s dependency on mitochon-
drial oxidative phosphorylation for ATP (Mathupala et al., 2006).
These findings raised the possibility that metformin would inhibit
theability ofTSC2/cells to formcolonies insoft agar, a measureCof malignantly transformed cells. Metformin was as effective
in blocking colony formation of TSC2+/ang1 cells (Figure 3E),
derived from a Tsc2+/ mouse spontaneous sarcoma (Govindar-
ajan et al., 2003), and mTORC1 signaling (Figures 3F), as rapamy-
cin. Thus, metformin inhibits mTORC1 signaling in a TSC-inde-
pendent manner.
AMPK Is Sufficient, but Not Necessary,
for mTORC1 Inhibition by Energy-Depleting Agents
Recent studies have shown that 5-aminoimidazole-4-carboxa-
mide-1-b-D-ribofuranoside (AICAR), through activation of
AMPK, induces raptor phosphorylation, causing it to be se-
questered by 14-3-3 proteins and inactivating mTORC1 (Gwinn
et al., 2008). AICAR is metabolized to ZMP, an AMP analog that
mediates the activation of AMPK (Hardie, 2008). Consistent with
these findings, ectopic expression of either of two constitutively
active AMPK mutants, g1 R70Q or g1 R152Q, strongly inhibited
insulin-induced S6K1 T389 phosphorylation, and this inhibition
was paralleled by AMPK T172 phosphorylation (Figure 4A).
However, such studies, including those of pharmacological
intervention, are usually performed over extended times, raising
the possibility of indirect AMPK effects on mTORC1 signaling.
To test this possibility, we used C2C12 cells, a nontransformed
myoblast cell line, which responds acutely to both AICAR and
energy-depleting agents (Jakobsen et al., 2001). We observed
that AICAR induced rapid phosphorylation of AMPK T172 and
ACC S79, but there was a significant delay in S6K1 T389
dephosphorylation (Figure 4B), which was not evident following
2DG treatment (Figure 4C, see the Discussion). To test AMPK
dependence, we took advantage of AMPKa1
/:a2
/ MEFs
(AMPK dKO), which lack both catalytic subunits of AMPK
(Laderoute et al., 2006). DKO and WT MEFs showed an equiv-
alent dose-dependent dephosphorylation of S6K1 T389 upon
2DG treatment (Figure 4D), whereas AMPK T172 and ACC
S79 phosphorylation were only observed in WT MEFS. This
effect was also observed in Drosophila Kc167 cells, where
dsRNA depletion of dAMPK did not protect dTOR signaling
from energy depletion (Figure S2). Unlike TSC2/ MEFs, there
was no difference in the dephosphorylation of S6K1 T389 at
lower 2DG concentrations, supporting the argument that the
resistance seen in the TSC2/ MEFs is a TSC2-specific phe-
nomenon (Figure 2C). Similar inhibition of mTORC1 signaling
was found in AMPK dKO MEFs following glucose withdrawal
(Figure 4E). These findings strongly support a model in which
AMPK is dispensable for the inhibition of mTORC1 by glycolytic
blockage.
Metformin and Phenformin Inhibit mTORC1 Signaling
Independent of AMPK
Others have reported that phenformin inhibits mTORC1 sig-
naling through AMPK phosphorylation of raptor (Gwinn et al.,
2008). These findings suggest that the biguanides blunt
mTORC1 signaling in a manner that is distinct from the effects
of 2DG and glucose deprivation. However, we found that treat-
ment of AMPK dKO MEFs with either biguanide abolished
S6K1 T389 phosphorylation to the same extent as in AMPK
WT MEFs (Figures 5A and 5B). In AMPK dKO MEFs, as com-
pared to AMPK WT MEFs, neither agent had an effect on ACC
S79 phosphorylation (Figures 5A and 5B), supporting the notionell Metabolism 11, 390–401, May 5, 2010 ª2010 Elsevier Inc. 393
Figure 3. Metformin and Phenformin Inhibit mTORC1 Signaling Independent of TSC2
(A and B) TSC2+/+ or TSC2/ MEFs were treated with either (A) 10 mM metformin for 24 hr or (B) 6 mM phenformin for 1 hr.
(C) TSC2/ MEFs seeded at increasing density (1.25 3 104, 5 3 104, or 20 3 104 cells/well) were treated as in (A).
(D) TSC2/ MEFs seeded at 20 3 104 cells/well and treated with 10 mM metformin for 24 hr in either the initial or fresh medium.
(E) TSC2+/ang1 cells were allowed to grow in soft agar for 3 weeks, with or without 20 nM rapamycin or 10 mM metformin. Colonies were stained with MTT and
counted as described in the Experimental Procedures.
(F) TSC2+/ang1 cells were treated with either 20 nM rapamycin for 15 min or 10 mM metformin for 24 hr. Western blots were performed as described in the
Experimental Procedures and probed with the indicated antibodies. The data shown are representative of at least two independent experiments.
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to inhibit mTORC1 signaling. It should be noted that, despite
the absence of AMPK, such treatment did not have a more
pronounced effect on the energy status of AMPK dKO versus
AMPK WT MEFs (Figure S3A). Unlike the biguanides, AICAR
had no effect on insulin-stimulated S6K1 T389 dephosphoryla-
tion in AMPK dKO MEFs, verifying the specificity of AICAR for394 Cell Metabolism 11, 390–401, May 5, 2010 ª2010 Elsevier Inc.AMPK as well as the complete loss of AMPK function in these
cells (Figure 5C). Moreover, this effect was not confined to
S6K1 T389 phosphorylation, as similar results were observed
for 4E-BP1, as measured by its electrophoretic mobility (Fig-
ure 5C). Consistent with the findings of Gwinn et al. (Gwinn
et al., 2008), we found that phenformin induced raptor S792
phosphorylation, which paralleled inhibition of S6K1 T389
Figure 4. AMPK Is Sufficient to Inhibit
mTORC1 Signaling, but It Is Not Required
for mTORC1 Inhibition by Energy Depletion
(A) WT indicates HEK293 cells in which a, b, and g
subunits of AMPK were coexpressed for 40 hr.
R70Q and R172Q indicate that the WT g subunit
was substituted with the respective g mutants.
After 24 hr of ectopic expression, cells were
deprived of serum overnight and stimulated with
200 nM insulin for 30 min. C2C12 myoblasts were
treated with either (B) 2 mM AICAR or (C) 25 mM
2DG for the indicated times. (D) Primary AMPK
a1 and a2 double knockout (AMPK dKO) and
AMPK WT MEFS were treated with 2DG for
30 min at the indicated concentrations. (E) Immor-
talized AMPK dKO and AMPK WT cells were
starved of glucose for 1 hr. Western blots were per-
formed as described in the Experimental Proce-
dures and using the indicated antibodies. The
data shown are representative of at least two
independent experiments.
Cell Metabolism
Metformin Inhibits mTORC1 Independent of AMPKphosphorylation in AMPKWTMEFs (Figure 5D). However, phen-
formin did not induce raptor S792 phosphorylation inAMPK dKO
MEFs, despite abolishing S6K1 T389 and 4E-BP1 phosphoryla-
tion (Figure 5D). Finally, mTORC1 derived from insulin-stimu-
lated AMPK dKO MEFs, as compared to AMPK WT MEFs,
showed elevated in vitro S6K1 T389 phosphorylation activity,
which was unaffected by AICAR pretreatment but was abolished
with phenformin (Figure 5E). This led to the finding that metformin
was just as efficient as rapamycin in blocking colony formation
of AMPK dKO MEFs in soft agar (Figure S3B). Taken together,
the results show that the inhibitory effect of biguanides on
mTORC1 activity is AMPK independent.
Absence of AMPK Does Not Affect Metformin-Mediated
Glucose Uptake
The findings above have particular relevance in the treatment of
type 2 diabetes, where mTORC1/S6K1 hyperactivation has been
shown to induce insulin resistance through IRS1 phosphoryla-
tion (Harrington et al., 2004; Tremblay et al., 2007; Tzatsos andCell Metabolism 11, 390–Kandror, 2006; Um et al., 2006; Um
et al., 2004). As metformin treatment is
known to induce glucose uptake in skel-
etal muscle (Sakamoto et al., 2005;
Zhou et al., 2001), it was hypothesized
that, at least in part, these effects are
mediated by metformin-induced activa-
tion of the AMPK-TSC1/2 axis and inhibi-
tion of mTORC1/S6K1 phosphorylation
of IRS1 (Tzatsos and Kandror, 2006).
To examine the role of AMPK in glucose
uptake in L6 myotubes, the AMPKa1/a2
catalytic subunits were depleted by
siRNA treatment, with such treatment
abolishing AICAR-induced ACC S79
phosphorylation and S6K1 T389 dephos-
phorylation (Figure 6A). However, metfor-
min treatment still inhibited S6K1 T389phosphorylation but had no effect on ACC S79 phosphorylation
in L6 myotubes depleted of AMPKa1/a2 (Figure 6A). Importantly,
depletion of AMPKa1/a2 had no measurable effect on glucose
uptake induced by metformin, whereas AICAR-induced glucose
uptake is largely abolished (Figure 6B). The data presented here
suggest that AMPK is not essential for the effects of metformin
on glucose uptake.
Metformin and Phenformin Inhibit RAG
GTPase-Mediated mTORC1 Signaling
In the search for potential mitochondria-dependent mechanisms
by which biguanides reduce mTORC1 signaling, we analyzed
the role of redox status (Sarbassov and Sabatini, 2005) and
FKBP38 (Bai et al., 2007), a member of the FK506-binding
protein (FKBP) family. Although oxidizing agents, such as phe-
nylarsine oxide (PAO), raise basal levels of mTORC1 signaling,
they did not protect this response from the effects of either
glycolytic or mitochondrial oxidative phosphorylation inhibitors
(Figure S4A). Similarly, siRNA depletion of FKBP38 did not401, May 5, 2010 ª2010 Elsevier Inc. 395
Figure 6. Absence of AMPK Does Not Affect Metformin-Mediated
Glucose Uptake
(A) L6 myotubes were transfected with either nonsilencing dsRNA (NS) or with
two different dsRNAs directed against either the a1 or the a2 catalytic subunit
of AMPK and incubated for 72 hr. Cells were then treated with either 5 mM
metformin for the last 24 hr or 2 mM AICAR for the last 2 hr. Parallel plates
were either extracted for western blotting with the indicated antibodies or (B)
further processed for glucose-uptake measurements, as described in the
Experimental Procedures. Results are representative of three independent
experiments conducted in triplicate.
Figure 5. Metformin and Phenformin, but Not AICAR, Inhibit
mTORC1 Independent of AMPK
Western blot analysis of extracts from AMPK dKO or AMPK WT MEFs treated
either with (A) 10 mM metformin for 24 hr, (B and D) 6 mM phenformin for 1 hr,
or (C) 2 mM AICAR for 2 hr. (E) Serum-starved AMPK dKO or AMPKWT MEFs
treated for 1 hr with phenformin or AICAR were stimulated with insulin for
15 min. Raptor was immunoprecipitated, and in vitro mTORC1 activity was
assayed as described previously (Gulati et al., 2008; Sancak et al., 2007). In
parallel, western blot analyses were performed on cell lysates. The data shown
are representative of multiple independent experiments.
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(Figure S4B). Recently, it was shown that amino acids activate
a novel family of GTPases, termed Rags, to stimulate mTORC1
signaling (Kim et al., 2008; Sancak et al., 2008). The ability of
Rag GTPases to mediate this response is based on their
capacity to induce translocation of mTORC1 to a perinuclear
intracellular compartment occupied by Rheb (Sancak et al.,
2008). We found in growing cells that mTOR localized to large
perinuclear aggregates, whereas, upon removal of amino acids,
mTOR diffused throughout the cytoplasm, an effect reversed
by readdition of amino acids (Figure 7A). The specificity of
the mTOR polyclonal antibody signal was confirmed by delet-
ing mTOR in Cre+-mTORfl/fl MEFs, which largely abolished
mTOR staining by immunofluorescence or western blot analysis
(Figure S4C). Similar to the effect of amino acid withdrawal,
treatment of cells growing in complete media with phenformin396 Cell Metabolism 11, 390–401, May 5, 2010 ª2010 Elsevier Inc.caused mTOR to disperse throughout the cytoplasm (Figure 7A
and Figure S4D). Although phenformin phenocopied amino
acid withdrawal, it had no effect on amino acid steady-state
levels (Figures S4E and S4F). To test whether the inhibitory
effects of phenformin on mTORC1 signaling are mediated
by the Rag GTPases, we compared the ability of transiently
expressed wild-type HA-GST-RagB versus a constitutively acti-
vated HA-GST-RagB construct to protect phosphorylation of a
GST-tagged S6K1 T389 reporter from either amino acid with-
drawal or phenformin treatment. We found that amino acid
withdrawal or phenformin treatment almost totally abolished
reporter S6K1 T389 phosphorylation in cells transfected with
the empty vector (Figure 7B). Cotransfection of either constitu-
tively active or wild-type HA-GST-RagB slightly raised basal
levels of reporter S6K1 T389 phosphorylation; however, only
constitutively activated HA-GST-RagB protected against amino
acid withdrawal and phenformin treatment (Figure 7B). Similar
results were obtained with treatment of oligomycin (Figure S4G).
These findings support a role for biguanides in suppressing
mTORC1 signaling through inhibition of Rag function, as depicted
in Figure 7C.DISCUSSION
The Acute and Chronic Response to Energy Depletion
The acute response to energy depletion is transient inDrosophila
Kc167 cells and in mammalian cells (Figures 1 and 2). Although
Figure 7. Rag GTPases Mediate the Inhibition of mTORC1 by Phen-
formin
(A) HEK293T cells were either starved for serum and amino acids for 50 min
(AA) and restimulated with amino acids for 10 min (AA/+AA), or cells in
full media treated with 5 mM phenformin for 1 hr. Cells were processed as
described in the Experimental Procedures, and immunofluorescence assays
were performed to detect mTOR (green).
(B) HEK293T cells expressing epitope-tagged HA-GST-RagB GTP mutant
or HA-GST-RagB WT were either deprived of amino acids or treated with
5 mM phenformin for 1 hr. PPK5 empty vector served as a control. Western
blots were performed as described in the Experimental Procedures, and
proteins were detected with the indicated antibodies. These studies are repre-
sentative of at least two independent experiments.
(C) Model for metformin/phenformin action on mTORC1.
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Cmitochondrial oxidative phosphorylation, as compared to glycol-
ysis, is the most efficient mechanism to produce ATP, most
cultured cells depend on both processes to generate energy
(Schieke et al., 2006). We found that readdition of the same
energy-depleting agent during the recovery period had little
effect on mTORC1 signaling or on AMPK activation, whereas
addition of the alternative inhibitor had immediate effects on
both responses (Figures 2E and 2F). These data imply that
mTORC1 signaling is sensitive to both sources of energy
production and that inhibition by either is restored by the upregu-
lation of the alternate energy-generating system. Although the
rise in the AMP/ATP ratio did not directly reflect the extent of
mTORC1 signaling inhibition, the addition of both inhibitors
together led to a dramatic rise in this response (A.K. and G.T.,
unpublished data). In addition to the acute response, a second,
chronic energy-depletion response, which is mediated by the
tumor suppressor, regulated in development and DNA damage
responses (REDD1) (Sofer et al., 2005) in a TSC1/TSC2-depen-
dent manner, has been described. REDD1 suppresses mTORC1
activity by releasing TSC2 from 14-3-3 protein inhibition
(DeYoung et al., 2008). Unlike TSC1/TSC2, the role of AMPK in
the chronic energy response has been ambiguous, because
a dominant-interfering AMPK blocks long-term 2DG inhibition
of mTORC1 signaling, but an inducible REDD1 construct is
able to bypass this block (Sofer et al., 2005). It does not appear
that AMPK acts upstream to regulate REDD1, as Sofer et al.
could not detect any changes in REDD1 levels or other modifica-
tions of the protein following 2DG treatment in the presence of
a dominant-interfering AMPK (Sofer et al., 2005). The use of
AMPK dKO MEFs will be valuable in addressing the chronic
energy response.HKII Upregulation in TSC2-Deficient MEFs
We first proposed a model by which mTORC1 was controlled by
ATP levels (Dennis et al., 2001). However, later studies showed
that AMPK phosphorylates TSC2, potentially increasing TSC2
GAP activity toward Rheb (Inoki et al., 2003). In these latter
studies, 25 mM 2DG had little inhibitory effect on mTORC1
signaling in TSC2/ MEFs (Inoki et al., 2003). Here we also
noted that treatment with lower concentrations of 2DG attenu-
ated inhibition of mTORC1 signaling in TSC2/ MEFs. However,
such cells are known to express elevated levels of HIF-1a
(Brugarolas et al., 2003), which can drive the expression of
HKII, whose ability to bind glucose is inhibited by 2DG (Wick
et al., 1957). This inhibition is the basis of phase 1 clinical trials
employing 2DG in the treatment of tumors that exhibit increased
glycolysis (Maher et al., 2007). Thus, the increase in HKII levels
may explain the requirement for a higher concentration of
2DG to achieve inhibition of mTORC1 signaling (see below), as
has been shown in resistant tumor cell lines under conditions
in which HIF-1a is induced by hypoxia (Maher et al., 2007).
Such substrate-induced resistance is observed for other chemo-
therapeutic agents, including methotrexate, where increased
expression of dihydrofolate reductase leads to drug resistance
(Bertino et al., 1983). This model may also explain why
decreasing glucose in the culture media increases the sensitivity
of TSC2/ MEFs to lower concentrations of 2DG (Smith et al.,
2005).ell Metabolism 11, 390–401, May 5, 2010 ª2010 Elsevier Inc. 397
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in TSC2-Deficient Cells
We find that biguanides inhibit mTORC1 signaling in a TSC2-
independent manner. Efforts to reconcile this observation with
that of Dowling et al. (Dowling et al., 2007) led to our finding
that, as the density of cells in culture increases, mTORC1
signaling in TSC2-deficient cells acquires sensitivity to metfor-
min inhibition (Figures 3C and 3D). The increased demand for
oxygen as a function of cell density leads to a hypoxic environ-
ment and the induction of HIF-1a (Dayan et al., 2009; Paltoglou
and Roberts, 2005), an effect readily reversed by increasing the
available oxygen or inhibiting oxygen consumption by oligomy-
cin treatment (Dayan et al., 2009). In TSC2/ MEFs, basal levels
of HIF-1a are elevated, as are a number of HIF-1a target genes,
an effect that is strongly potentiated by hypoxia (Brugarolas
et al., 2003). We found that as TSC2/ MEFs became
confluent, the levels of HKII, a HIF-1a target, increased approx-
imately 2-fold (Figure S1). In most tumor cells, under aerobic
conditions, glycolysis is upregulated to generate glycolytic inter-
mediates, required as biosynthetic building blocks (Mathupala
et al., 2006, 2009). An early step in tumorigenesis is the switch
from the use of HK-IV (glucokinase) to HKII (Mathupala et al.,
2006, 2009), the latter having a much higher affinity for glucose,
increasing the rate of glucose-6 phosphate production. The
increased ATP required for the production of glucose-6 phos-
phate is channeled from the mitochondrial ATP synthase to the
porin-like protein voltage-dependent anion channel (VDAC),
which localizes HKII to the outer mitochondrial membrane
(Mathupala et al., 2006). Under these conditions, the tumor
cell would be predicted to become more sensitive to inhibitors
of mitochondrial oxidative phosphorylation. The increase in
HKII may explain the acquired sensitivity to metformin of
mTORC1 signaling as TSC2/ MEFs become confluent (Fig-
ure 3C). In preliminary studies we found that partial siRNA
depletion of HKII in TSC2/ MEFs afforded mTORC1 some
protection from inhibition by metformin (A.K. and G.T., unpub-
lished data); however, a more in-depth analysis will be required
to understand the role of HKII on density-dependent sensitivity.
The difference in metformin sensitivity prompted us to test the
efficacy of the drug in a TSC-deficient setting, and found that
metformin inhibits colony formation to the same extent as rapa-
mycin. It would be of interest to determine, through clinical
registries, whether TSC patients being treated for diabetes
with metformin showed any alleviation of TSC syndromes.
This may be of clinical importance, as extended rapamycin
treatment is known to suppress pancreatic b cell adaptation to
hyperglycemia and to exacerbate type 2 diabetes (Fraenkel
et al., 2008).
The Effect of Biguanides on mTORC1 Signaling
in AMPK-Deficient Cells
Our findings in C2C12 cells showed that AICAR-induced S6K1
T389 dephosphorylation is modest and delayed, as compared
to the rapid phosphorylation of AMPK T172 and ACC S79
(Figure 4C), suggesting that the effects of AMPK on mTORC1
are indirect. Moreover, that the kinetics of 2DG-induced inhibi-
tion of mTORC1 signaling were so much more rapid than those
induced by AICAR (Figures 4B and 4C), despite similar effects
on ACC S79 phosphorylation, led to the notion of an alternative398 Cell Metabolism 11, 390–401, May 5, 2010 ª2010 Elsevier Inc.AMPK-independent mechanism for acute energy depletion.
This was substantiated in AMPK dKO MEFs, where energy-
depleting agents, but not AICAR, blocked S6K1 T389 phosphor-
ylation (Figure 5). Moreover, although metformin induced raptor
S792 phosphorylation in AMPKWTMEFs, this response was not
detected in AMPK dKO MEFS. On the basis of these observa-
tions, we conclude that biguanides do not require TSC1/TSC2
to inhibit mTORC1 signaling and, although AMPK activation is
sufficient to attenuate mTORC1 signaling, it is not essential for
these responses.
Inhibition of mTORC1 by Biguanides Is Dependent
on the Rag GTPases
A search for alternative mechanisms for biguanide action led to
a study of redox status, which was shown to affect the interac-
tion between raptor and mTOR in a manner similar to nutrients,
including amino acids and glucose (Kim et al., 2002; Sarbassov
and Sabatini, 2005). Although the cell-permeable oxidant PAO
increased basal levels of S6K1 T389 phosphorylation, treatment
of cells with either oligomycin or 2DG induced dephosphoryla-
tion to the same extent as in non-PAO-treated cells (Figure S4A).
This argued against the involvement of redox status in mediating
inhibition of mTORC1 by energy depletion. We also examined
the potential role of FKBP38, which contains a mitochondrial
targeting sequence and has recently been described as a nega-
tive regulator of mTORC1 by sequestering Rheb (Bai et al.,
2007). However, siRNA depletion of FKBP38 did not protect
mTORC1 signaling from either the glycolytic or mitochondrial
oxidative phosphorylation inhibitors, suggesting that it does
not convey the energy-depletion signal to mTORC1 (Figure S4B).
Given that glucose deprivation affects the interaction between
raptor and mTOR and the kinase activity of the raptor-mTOR
complex in a manner similar to amino acid withdrawal (Kim
et al., 2002; Sarbassov and Sabatini, 2005), we reasoned that
the Rag GTPases might be involved in the metformin inhibitory
response. Rag GTPases have been shown to direct mTORC1
to a cellular compartment that contains Rheb, leading to kinase
activation (Sancak et al., 2008). Consistent with this possibility,
we found that, similar to amino acid withdrawal, phenformin
treatment caused mTOR to disperse from perinuclear aggre-
gates and diffuse throughout the cytoplasm (Figure 7A). More-
over, although Sancak et al. concluded that energy-depleting
agents, such as 2DG, appeared not to mediate their inhibitory
affects through the Rag GTPases (Sancak et al., 2008), we
found that ectopic expression of a constitutively active, but
not wild-type (WT), Rag GTPase protected mTORC1 signaling
from inhibition by phenformin and oligomycin (Figure 7B and
Figure S4G).
Metformin, mTORC1 Signaling, and Glucose Uptake
Metformin is argued to lower hyperglycemia by inhibiting hepatic
gluconeogenesis and increasing glucose uptake in skeletal
muscle (Zhou et al., 2001). These effects are attributed to activa-
tion of AMPK, and, in the case of hepatic gluconeogenesis,
recent studies in LKB1/-deficient mice support such a model
(Shaw et al., 2005). However, it should be noted that the effects
of metformin on glucose phosphorylation in AMPK dKO hepato-
cytes are AMPK independent (Guigas et al., 2006). In the case of
increased glucose uptake in skeletal muscle, both mTORC1 and
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the phosphorylation of IRS1 (Um et al., 2006). Metformin, as
well as 2DG, has been shown to reverse the effects of mTORC1
phosphorylation on two IRS1 sites known to antagonize PI3K
binding to IRS1 (Tzatsos and Kandror, 2006). Given that both
agents induced increased AMPK T172 phosphorylation, it was
concluded that the effects of metformin and 2DG were mediated
by activation of LKB1 and AMPK (Tzatsos and Kandror, 2006).
However, we found that both metformin and phenformin
inhibited mTORC1 signaling in the absence of AMPK (Figures
5A and 5B). Additionally, we found that depletion of AMPKa1/
a2 catalytic subunits did not block the metformin-enhanced
increase in glucose uptake (Figure 6). Taken together, these
studies reveal the existence of an alternative TSC1/2-AMPK-
independent pathway, potentially mediated by RAG GTPase,
which responds rapidly to perturbations in energy status to
maintain homeostatic mTORC1 signaling.
In summary, the studies presented here reveal a novel mech-
anism by which metformin inhibits mTORC1 signaling. Given that
more than 100 million individuals are treated daily for type 2 dia-
betes with metformin, and that its use may be extended to the
treatment of specific cancers (Shackelford and Shaw, 2009), it
is critical to determine its mode of action. Therefore, elucidating
the mechanism by which inhibition of Rag GTPases by metfor-
min suppress mTORC1 signaling could be beneficial in the treat-
ment of particular human pathologies.
EXPERIMENTAL PROCEDURES
Materials
Reagents were from the following sources: bovine insulin, 2DG, metformin, and
phenformin from Sigma Aldrich; rapamycin from Calbiochem; oligomycin from
Calbiochem and Acros; AICAR from Toronto Research Chemicals; antibodies
to phospho-T389 S6K1, phospho-T172 AMPK, AMPK, phospho-S79 ACC1/2,
TSC2, and phospho-T398 dS6K from Cell Signaling Technology; and anti-
bodies to S6K1, HKII, and 4E-BP1 (R113) from Santa Cruz Biotechnology.
The monoclonal tubulin E7 antibody was from the Developmental Studies
Hybridoma Bank, National Institute of Child Health and Human Development
(NICHD), maintained by The University of Iowa. The Drosophila TSC1 antibody
was from D. Pan (Johns Hopkins). The expression vectors for the WTa, b, and g
subunits of AMPK and the g subunit mutants R70Q and R172Q have been
described (Adams et al., 2004). The expression vectors pRK5-HA GST
RagB 99L and pRK5-HA GST RagB 54L were from D. Sabatini, and the WT
pRK5-HA GST RagB vector was from Addgene. 2-deoxy-D-[3H]glucose was
from NEN Life Science. Calcium phosphate-based transfection reagent Cell-
Phect was from GE Healthcare. AMPK a1 and a2 siRNA sequences were
GCAUAUGCUGCAGGUAGAUdtdt (nucleotides 738–756, accession number
NM_019142) and CGUCAUUGAUGAUGAGGCUdtdt (nucleotides 865–883,
accession number NM_023991), respectively.
Cell Culture, Treatments, and Transfections
TSC2+/+/P53/ and TSC2//P53/ MEFs were obtained from D. Kwiatkow-
ski (Harvard Medical School). AMPK WT MEFs and AMPK dKO, have been
previously described (Laderoute et al., 2006). All mammalian cell lines were
grown in DMEM high glucose supplemented with 10% fetal bovine serum
(FBS) and 50 mg/ml of a Pen/Strep mix, except for L6 cells, which were grown
in a-MEM with the same additives. Typically, 6-well plates were seeded at
105 cells per well and inhibitors were directly added to the medium after 48 hr
growth. Glucose starvation was performed using glucose and pyruvate-free
medium. All exogenously expressed cDNAs were transfected using Fugene
6 (Roche) according to the manufacturer’s instructions. AMPK a1, a2 siRNA
treatments were carried out on L6 myoblasts seeded in 12-well plates, using
CellPhect according to the manufacturer’s instructions. Six hours posttrans-
fection, the medium was replaced with a-MEM supplemented with 2% FBSCto induce differentiation, and treatments were performed 72 hr posttransfec-
tion. Glucose uptake measurements were performed as described previously
(Bedard et al., 1997).
Cell Extraction and Western Blotting
All mammalian cell extracts were prepared with the ELB extraction buffer:
50 mM Tris (pH 7.5), 0.1% NP-40, 120 mM NaCl, 1 mM EDTA, 6 mM EGTA,
20 mM NaF, 1 mM Na pyrophosphate, 30 mM 4-nitrophenyl phosphate,
1 mM benzamidine, and one tablet of EDTA-free protease inhibitor cocktail
(Roche) per 25 ml of buffer. Cells were rinsed twice with ice-cold PBS and
extracted on ice with ELB buffer. Typically, cell extracts were kept at 80C
overnight and the soluble fractions cleared of debris the following day with
a 14,000 rpm spin for 10 min at 4C. A stock of the extract was made in 13
Laemmli buffer and either stored at 20C or 10–30 mg of protein used for
western blot analysis.
Drosophila
DrosophilaKc167 cells were maintained as described (Radimerski et al., 2002).
Preparation of protein extracts from cells and dS6K kinase activity was
measured as previously described (Radimerski et al., 2002). H2B was used
as a substrate for the assay. Treatment with dsRNA was performed essentially
as described (Radimerski et al., 2002), with an incubation time of 7 days.
All primers contain the T7 RNA polymerase binding site, 50-TTAATAC
GACTCACTATAGGGAGA-30 dTsc1, accession number AF173560, sense
primer 436–453, antisense primer 1081–1098; dTsc2, accession number
AF172995, sense primer 591–608, antisense primer 1371–1388.
Confocal Microscopy
HEK293T cells were seeded in 6 cm dishes containing fibronectin-coated
glass coverslips. Cells were treated as indicated 36 hr postseeding and pro-
cessed as described previously (Sancak et al., 2008). The coverslips were
mounted on glass slides using Vectashield (Vector Laboratories) and images
recorded using a Zeiss LSM 510 Meta confocal microscope with the appro-
priate filter settings.
Anchorage-Independent Growth Assay
Colony formation assays were performed in 6-well plate format where 1 ml of
DMEM/10% FBS containing 0.5% Difco Agar Noble (Becton Dickinson) was
allowed to set as a base agar layer. Trypsinized cells were then resuspended
in 1 ml of DMEM/10% FBS containing 0.3% agar at either 40,000 (TSC2+/
ang1) or 60,000 cells/ml (WT and AMPK dKO), supplemented with the desired
inhibitor and poured over the base layer. Plates were then incubated overnight
at 37C, 5% CO2, and 0.5 ml of DMEM/10% containing the desired inhibitor
was then overlaid on top of the agar and replaced every 3 days. Colonies
were stained by first washing the agar with 37C PBS, then incubating the
plates with PBS containing 0.5 mg/ml MTT for 4 hr at 37C. Colony numbers
were determined using the AxioVision software (Carl Zeiss Vision).
Sequence Analysis
Alignment of the TSC2 sequences and the AMPK phosphorylation motif
search were carried out using Vector-NTI software (InforMax).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article at doi:10.1016/j.cmet.2010.03.014.
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